Matches in SemOpenAlex for { <https://semopenalex.org/work/W623866857> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W623866857 endingPage "633" @default.
- W623866857 startingPage "625" @default.
- W623866857 abstract "Lipoprotein (a), Lp (a), is a variant from of LDL that contains apo (a). Elevated plasma levels of Lp (a) are considered to be an independent risk factor for the development of cardiovascular disease.We studied the effect of niceritrol, a nicotinic acid derivative, on serum Lp (a) levels in 98 patients with hyperlipidemia. The dosage of niceritrol was increased every 4 weeks (e. g., from 750mg to 1, 500mg to 2, 250mg/day). The final dosage was adjusted to achieve good control or good compliance with each patient.Niceritrol therapy of 16 weeks leads to a significant decrease in serum levels of Lp (a), from 24.1±2.6mg/dl to 15.5±2.3mg/dl. In the group with pre-treatment level of Lp (a) over 20mg/dl, the reduction rate of Lp (a) was 8.9%, 22.6% and 31.5% at doses of 750mg, 1, 500mg and 2, 250mg/day, respectively. It is suggested that a reduction in the Lp (a) level is related to the dosage of niceritrol and the pretreatment level of Lp (a).In conclusion, niceritrol therapy proved to be effective in a dose-dependent manner for reducing the Lp (a) level as well as for improving other lipid characteristics." @default.
- W623866857 created "2016-06-24" @default.
- W623866857 creator A5002602126 @default.
- W623866857 creator A5020418585 @default.
- W623866857 creator A5021695554 @default.
- W623866857 creator A5023583467 @default.
- W623866857 creator A5026436258 @default.
- W623866857 creator A5028164135 @default.
- W623866857 creator A5030977813 @default.
- W623866857 creator A5032976336 @default.
- W623866857 creator A5040439577 @default.
- W623866857 creator A5042661843 @default.
- W623866857 creator A5043635319 @default.
- W623866857 creator A5046466446 @default.
- W623866857 creator A5059142600 @default.
- W623866857 creator A5065124212 @default.
- W623866857 creator A5071212952 @default.
- W623866857 creator A5071445429 @default.
- W623866857 creator A5073704512 @default.
- W623866857 creator A5074311817 @default.
- W623866857 date "1992-01-01" @default.
- W623866857 modified "2023-10-18" @default.
- W623866857 title "Effect of Niceritrol (Perycit®) on Serum Levels of Lipoprotein (a): Assessing the Effect of Gradually Increased Dosages" @default.
- W623866857 cites W1583758928 @default.
- W623866857 cites W2002259048 @default.
- W623866857 cites W2004838889 @default.
- W623866857 cites W2019295985 @default.
- W623866857 cites W2036170644 @default.
- W623866857 cites W2060132183 @default.
- W623866857 cites W2067318301 @default.
- W623866857 cites W2115572248 @default.
- W623866857 cites W2116404316 @default.
- W623866857 cites W2117245915 @default.
- W623866857 cites W2156315439 @default.
- W623866857 cites W2321230622 @default.
- W623866857 cites W2324712847 @default.
- W623866857 cites W2329533302 @default.
- W623866857 cites W2396975380 @default.
- W623866857 cites W2398473790 @default.
- W623866857 doi "https://doi.org/10.5551/jat1973.20.6-7_625" @default.
- W623866857 hasPublicationYear "1992" @default.
- W623866857 type Work @default.
- W623866857 sameAs 623866857 @default.
- W623866857 citedByCount "0" @default.
- W623866857 crossrefType "journal-article" @default.
- W623866857 hasAuthorship W623866857A5002602126 @default.
- W623866857 hasAuthorship W623866857A5020418585 @default.
- W623866857 hasAuthorship W623866857A5021695554 @default.
- W623866857 hasAuthorship W623866857A5023583467 @default.
- W623866857 hasAuthorship W623866857A5026436258 @default.
- W623866857 hasAuthorship W623866857A5028164135 @default.
- W623866857 hasAuthorship W623866857A5030977813 @default.
- W623866857 hasAuthorship W623866857A5032976336 @default.
- W623866857 hasAuthorship W623866857A5040439577 @default.
- W623866857 hasAuthorship W623866857A5042661843 @default.
- W623866857 hasAuthorship W623866857A5043635319 @default.
- W623866857 hasAuthorship W623866857A5046466446 @default.
- W623866857 hasAuthorship W623866857A5059142600 @default.
- W623866857 hasAuthorship W623866857A5065124212 @default.
- W623866857 hasAuthorship W623866857A5071212952 @default.
- W623866857 hasAuthorship W623866857A5071445429 @default.
- W623866857 hasAuthorship W623866857A5073704512 @default.
- W623866857 hasAuthorship W623866857A5074311817 @default.
- W623866857 hasBestOaLocation W6238668571 @default.
- W623866857 hasConcept C185592680 @default.
- W623866857 hasConceptScore W623866857C185592680 @default.
- W623866857 hasIssue "6-7" @default.
- W623866857 hasLocation W6238668571 @default.
- W623866857 hasOpenAccess W623866857 @default.
- W623866857 hasPrimaryLocation W6238668571 @default.
- W623866857 hasVolume "20" @default.
- W623866857 isParatext "false" @default.
- W623866857 isRetracted "false" @default.
- W623866857 magId "623866857" @default.
- W623866857 workType "article" @default.